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Objectives: To determine differences in the control of multiple diabetes control parameters in a select group of subjects with type 
2 diabetes (T2DM) after a four-year follow-up period.
Design: Cross-sectional study.
Setting and subjects: The initial 2009 study population consisted of 666 T2DM patients of whom only 261 (39.2%) were audited at 
the Charlotte Maxeke Johannesburg Academic Hospital.
Outcome measures: Using a public sector database, retrospective data were obtained on the treatment of participants with T2DM 
attending a tertiary care setting and a descriptive analysis was done.
Results: The mean age was 64 (SD 10.6) years, women represented 55% of the cohort and the mean duration of diabetes was 
16 years (range 2–40 years) in 2013. Fewer patients achieved an HbA1c goal (of < 7%) in 2013 (15.5%) compared with 2009 (25.4%), 
whilst an additional 13.7% and 25.0% of the 261 patients reached blood pressure targets (< 140/80 mmHg) and LDL-C targets 
( < 2.5 mmol/L), respectively.
Conclusion: Overall, more patients in the study reached blood pressure and LDL-C targets but there were difficulties in achiev-
ing optimal glycaemic levels over the four-year period. This study highlights the complexities of managing risk factors in T2DM, 
especially glucose control.
Keywords: diabetes mellitus, management, risk factors, targets
Introduction
South Africa has a staggering 3–10% prevalence rate of type 2 
diabetes mellitus (T2DM) amongst its urban and peri-urban 
population.1 In addition to risk factors such as raised blood 
pressure (BP) and glycaemic levels, dyslipidaemia is the primary 
cause of morbidity and mortality in T2DM patients.2 Randomised 
clinical trials have convincingly demonstrated that effective 
glycaemic control decreases microvascular complications, whilst 
treatment of blood pressure and dyslipidaemia reduces the 
incidence of cardiovascular complications.3,4 For this reason, clinical 
trial results have been incorporated into evidence-based 
guidelines that advocate intensified treatment of these risk 
factors.5
Despite strong evidence of improved outcomes through 
lifestyle and medication effectiveness, only a minority of total 
T2DM patients in clinical practice reach target goals.6 Risk-factor 
management as recommended by guidelines is often neglected, 
e.g. insufficient testing, physician reluctance to initiate or intensify 
pharmacotherapy, poor patient education or counselling and 
general lack of follow-up visits to evaluate response of the 
intervention. Clinical trials are often characterised by more 
frequent follow-up visits, motivated practitioners/patients and 
protocols that are more aggressive at targeting risk factors. 
Perhaps this difference is what complicates translating robust 
evidence into clinical practice.
The objective of this study was to audit and compare the 
achievement of targets of individual control parameters in a select 




This study was a continuation of a previous 2009 cross-sectional 
study, which can be considered as a baseline.7 The study was 
designed to further evaluate the extent to which diabetes 
guidelines were followed in a cohort of tertiary-based T2DM 
patients. Using patient records, the latest levels of blood 
pressure, glycated Hb (HbA1c) and lipid levels in treated patients 
were obtained. Achievement of treatment targets at the two 
points in time was compared.
Setting
The study was conducted at Charlotte Maxeke Johannesburg 
Academic Hospital (CMJAH) between May and October 2013. 
Patients normally attend the hospital’s diabetes clinic every 
3–6 months, depending on their individual treatment requirements. 
The authors of this study assumed that the patients 
attending this particular diabetes clinic required a level of care not 
normally offered in a primary care setting (as T2DM is a 
progressive disease that brings about many challenges in 
managing this condition). This study was an audit conducted in 
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2013 over a five-month capture period, which permitted us to 
access data of patients previously seen in the 2009 audit. Medical 
practitioners, with the assistance of nurses at the clinic, were 
responsible for the care, prescribing and check-ups of diabetic 
patients attending the clinic.
Patients
In the 2009 audit, 666 patients with T2DM as defined by the 
guidelines at the time of the study were enrolled.7,8 Patients 
excluded in 2009 were: < 18  years of age, had type 1 diabetes, 
gestational diabetes, steroid-induced diabetes and chronic 
pancreatitis that had led to secondary diabetes. As one of the 
primary measurements was a serum lipid reading, a decision was 
taken to exclude patients with triglyceride levels > 4.5 mmol/L as 
this may have been a source of error when calculating low-density 
lipoprotein (LDL) cholesterol, as measured by the Friedewald 
formula,9 or could have been noncompliance with overnight 
fasting, leading to anomalous lipid values and, in particular, 
falsely low LDL cholesterol measurements. For the purposes of this 
study, patients with laboratory HbA1c results of ‘>14%’ were 
assigned an HbA1c of 14.0%.
Similarly to the previous audit, patients were considered lost to 
follow-up if their last recorded entry or appointment in their file 
was dated before 2011 (at least two years prior to the start of the 
2013 study).7 Patients were also lost to follow-up if their hospital 
records were missing or filed in the ‘non-returns’ section of the clinic, 
deceased or down-referred to a separate treatment facility. Patients 
from the earlier (n = 666) 2009 audit whose files were not found in 
the 2013 audit were excluded from the analysis of this current 
study. For the purposes of this study, the data from the 2009 audit 
were re-analysed to include and compare only those 261 patients 
found in the later audit.
Unfortunately, most patient files had missing details of weight, 
height, diet details and smoking status. These parameters, 
especially the first two, would have been used to calculate body 
mass index (BMI). On the same note, due to omitted waist 
measurements, patient classification of metabolic syndrome (MS) 
was also excluded from the study.10 As with the previous study, 
missing details of ethnicity from patient records were denoted as 
‘unknown’.7 Patients defined as having diabetic nephropathy 
using laboratory data, i.e. micro-albumin-to-creatinine ratios, 
serum creatinine concentrations or glomerular filtration rate (GFR) 
often proved inconsistent due to numerous patients not having 
these laboratory reports available in their records. It was also found 
that some patients were concurrently being managed at the 
hospital’s renal clinic, separate from the diabetic clinic. For the 
purposes of this study, patients deemed as having diabetic 
nephropathy were those patients who had one or more of the 
following in their records: chronic kidney disease (CKD), chronic renal 
disease (CRD), chronic renal failure (CRF), nephropathy and diabetic 
nephropathy. Current patients attending the diabetes clinic at the 
CMJAH were scheduled for their routine appointments at different 
times throughout the year, which meant that data captured from 
files for this 2013 audit were reliant on the latest information from 
patient files, from their last visit to the clinic. To the best of our 
knowledge, only the most recent records and laboratory reports of 
the patient were utilised for the purposes of this study. Data from 
patient records were entered into case report forms and later into a 
secure database at the University of the Witwatersrand, Faculty of 
Health Sciences, Johannesburg, South Africa. Prior to the study, the 
University of Witwatersrand’s Human Research Ethics Committee 
(HREC) granted ethical approval for the study.
Clinical parameters
Registered nurses were in charge of drawing of study patients' 
bloods using standardised techniques at the diabetes clinic. 
Patients were informed of the fasting requirements of laboratory 
tests before having their blood drawn for specific tests in prior 
appointments/visits.
As CMJAH is a state hospital, the National Health Laboratory Services 
(NHLS) was responsible for all the laboratory measurements of 
study patients. Once the results were available, the NHLS issued 
laboratory results delivered by hospital staff to the diabetes clinic 
and filed under respective patient files by clinic administration 
staff. HbA1c was measured using the Tina-Quant Haemoglobin 
A1c II immunological assay, fasting LDL-C was calculated by 
means of the Friedewald formula, fasting high density lipoprotein 
cholesterol was measured by direct enzymatic methods (3rd 
Generation), fasting total cholesterol was also measured by direct 
enzymatic methods and TG was measured by enzymatic colori-
metric methods. All measurements were done using the Modular 
Analyser P800 System (Roche Diagnostics-Hitachi, Mannheim, 
Germany). Blood pressure values were measured by registered 
nurses or treating doctors in accordance with the South African 
Hypertension Guidelines and the Seventh Report of the Joint 
National Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure (JNC VII).11,12 Once data were 
captured into case report forms, the Society for Endocrinology 
Diabetes and Metabolism of South Africa (SEMDSA) 2 Guidelines 
for T2DM treatment targets were applied to the cohort, namely 
HbA1c  <  7.0%, TC  <  4.5  mmol/L, LDL-C  <  2.5  mmol/L, 
HDL-C > 1.0 mmol/L (men), HDL-C > 1.2 mmol/L (women) and Tri-
glyceride < 1.7 mmol/L.
In patients with established vascular disease such as ischaemic 
heart disease, cerebrovascular disease or peripheral vascular 
disease, the LDL-C target was < 1.8  mmol/L. Hypertension was 
considered to be present if patients were receiving antihypertensive 
treatment.
In order to compare blood pressure levels across the two 
different time points, the 2012 SEMDSA targets of systolic 
BP < 140 mmHg and diastolic BP < 80 mmHg were applied to both 
the 2009/2013 data, as previously the SBP was < 130 mmHg. This 
allowed for a consistent target against which both data sets could 
be compared in order to evaluate achievement of these targets.
Statistical and data analysis
A descriptive analysis was conducted with summary measures 
such as mean (standard deviation, SD) calculated for age, gender, 
race, blood pressures, HbA1c and fasting lipids. The percentage 
of previous coronary artery disease (CAD), stroke, retinopathy, 
neuropathy and nephropathy history in patients was reported 
through frequency tabulations. Frequency tables of patient 
usage of chronic medication for the treatment of hyperglycae-
mia, hypertension and lipids as well as those receiving anti- 
platelet treatment were also produced. The percentage of patients 
reaching SEMDSA treatment goals for various clinical 
parameters was calculated. Where necessary, the chi-square 
test was used to investigate any associations with key measures. 
Microsoft Office Excel 2009 (Microsoft, Redmond, WA, USA) was 
utilised for creating the study’s databases and statistical analysis 
was done using Stata version 13 (64-bit) (StataCorp, College 
Station, TX, USA).
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Results
The initial 2009 study population consisted of 666 T2DM patients of 
whom only 39.2% (n = 261) were audited, 4 years later. The rest of 
the study population were assumed to have died, relocated or 
been down-referred to another healthcare facility and were 
therefore excluded from the analysis. This suggests that the 
almost 40% of patients followed up may differ significantly from 
the larger cohort of patients from the earlier baseline study. Data 
were captured twice over two time periods– once during the 2009 
audit, then once again during the 2013 audit. The data from the 
2009 audit were re-analysed to include only those 261 patients’ files 
that could be located in the 2013 audit. A comparison of the two 
data sets was conducted as part of this study. Of the 261 patients, 
the mean age was 64 (SD 10.6) years (Table 1). Women represented 
55% (n = 143/261) of the cohort and the mean duration of diabetes 
for the population was approximately 16 years in 2013. The study 
population consisted of the following patient ethnicities: African 
(42.9%), Caucasian (25.3%), Indians/Asian (26.1%) and Mixed 
Ancestry (5.7%).
Glucose management
Previously in 2009, 96.6% (n = 252/261) of patients had HbA1c 
measurements, whereas in 2013 it was found that all patients had 
HbA1c values present in their records. There were apparently no 
differences in the mean HbA1c of the study population after the 
four-year period (8.7% (±2.0) (2013) vs. 8.5% (±2.2) (2009), p = 0.063). 
In 2013, the mean HbA1c value for males was 8.8% (±2.0) compared 
with 8.3% (±2.2) in 2009, with the pattern not different for females 
[8.7% (±2.0) vs. 8.6% (±2.2)].
We note a declining trend with time in achieving the HbA1c goal 
(< 7%) among these patients. In 2013, it was observed that only 
15.5% compared with 25.4% in 2009 achieved the HbA1c goal 
(Figure 1), despite overall more insulin and oral hypoglycaemics 
being prescribed. Almost 70% (175) of patients remained above 
HbA1c target in 2009 and 2013, whilst only 13 patients (5.2%) 
improved their HbA1c in 2013 after not being at goal in 2009. There 
were 26 patients (10.3%) who improved and reached HbA1c targets 
in 2013.
Alone or in combination, more patients began to use oral 
hypoglycaemics with 79.7% in 2013 compared with 64.0% in 2009. 
Similarly, insulin utilisation also increased (80.1% vs. 71.6%) 
respectively. Of the total number of patients not at target for HbA1c 
in 2013, 86.2% were using insulin (p < 0.001). Patients using basal 
insulin (Actraphane®, Humulin 30/70®, Humulin-N® and 
Protaphane®) were using on an average of 0.64 units per kg, whilst 
for pre-meal insulin (Actrapid® and Humulin-R®), the dose was 0.78 
units per kg.
Table 1: Characteristics of type 2 diabetes patients
Year 2009  
(n = 261)
Year 2013  
(n = 261)
p-value
Age (years) 60 ± 10.6 64 ± 10.6 –
Female sex, n (%) 143 (55%) 143 (55%) –
Ethnicity: African/Caucasian/Asian or Indian/Mixed Ancestry (%) 42.9/25.3/26.1/5.7 42.9/25.3/26.1/5.7 –
Duration of diabetes (years) 12 ± 10.6 16 ± 10.6 –
CAD, n (%) 34 (13.0%) 58 (22.2%) < 0.05
Stroke, n (%) 6 (2.3%) 10 (3.8%) NS
Retinopathy, n (%) 18 (6.9%) 39 (14.9%) < 0.05
Neuropathy, n (%) 16 (6.1%) 42 (16.1%) < 0.05
Nephropathy, n (%) 24 (9.2%) 60 (23.0%) < 0.0001
HbA1c (%) 8.5 ± 2.2 8.7 ± 2.0 NS
SBP (mmHg) 134 ± 17.8 139 ± 22.0 < 0.05
DBP (mmHg) 78 ± 10.5 73 ±11.4 < 0.0001
Total cholesterol (mmol/l) 4.5 ± 1.1 4.0 ± 1.0 < 0.0001
Triglycerides (mmol/l) 1.7 ± 0.9 1.6 ± 1.2 NS
LDL Cholesterol (mmol/L) 2.6 ± 0.9 2.1 ± 0.9 < 0.0001
HDL Cholesterol (mmol/L) 1.2 ± 0.4 1.2 ± 0.3 NS
Glucose-lowering drugs
No orals, n (%) 94 (36.0%) 53 (20.3%) < 0.0001
1 oral, n (%) 114 (43.7%) 172 (65.9%) < 0.0001
≥ 2 orals, n (%) 53 (20.3%) 36 (13.8%) < 0.05
Insulin (with or without oral hypoglycaemic drugs), n (%) 187 (71.6%) 209 (80.1%) < 0.05
Cardiovascular drugs
Statin lipid-lowering drugs, n (%) 150 (57.5%) 203 (77.8%) < 0.001
Antihypertensive drugs, n (%) 236 (90.4%) 244 (93.5%) NS
ACE-inhibitors or ARBs, n (%) 208 (79.7%) 207 (79.3%) NS
Antiplatelet drugs, n (%) 128 (49.0%) 119 (45.6%) NS
Note: p-value for differences, significant if p-value < 0.05. CAD = coronary artery disease, DBP = diastolic blood pressure, HbA1c = haemoglobin 
A1c, HDL = high-density lipoprotein, LDL = low-density lipoprotein, NS = non-significant, SBP = systolic blood pressure, ACE = angiotensin converting 
enzyme, ARB = angiotensin receptor blockers.
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patients (vs. 2009, p < 0.001) started statins over the four-year period. 
Not surprisingly, the control of LDL-C for patients with previous 
CVD or stroke (target 1.8 mmol/L) improved by almost 30% in 2013.
In 2009, there seemed to be no apparent differences in statin usage 
amongst males and females (58.5% vs, 56.6%, p = 0.766, 
respectively), whilst in 2013 there was a marked difference (male 
70.3% vs. female 83.9%, p < 0.05). Gender subgroup analysis 
revealed that females were less controlled for LDL-C than the males 
for the entire study duration. The mean LDL-C of females 
(2.6  mmol/L (±0.9) vs. 2.2  mmol/L (±0.9), p < 0.05) and males 
(2.5  mmol/L (±0.9) vs. 2.1  mmol/L (±0.8), p < 0.05) improved 
respectively from 2009 to 2013.
As seen in the past, simvastatin continued to be the most frequently 
prescribed statin in 2013 (61.1% vs. 94.7% in 2009) with the 20 mg 
strength being the most prescribed. Atorvastatin usage increased 
from 5.3% to 38.9% over time, again with the 20 mg strength being 
the most frequently prescribed dose.
Discussion
As the global spread of diabetes propels out of control, this condition 
can undeniably be heralded as a pandemic. Developed countries 
have faced urbanisation and adoption of many unhealthy lifestyle 
choices leading to diabetes over the past few decades and South 
Africa is no exception to this. In order to identify where T2DM 
treatment gaps lie, this study aimed to determine the disparities of 
management of diabetes control parameters in a cohort of 
complicated T2DM patients after a four-year period at a state-run 
tertiary hospital. Given this, we found that hypertension and lipid 
targets were more easily achieved, whereas glycaemic control was 
harder to achieve, with fewer patients achieving adequate glycaemic 
control after the four-year period.
Diabetes is a progressive disease that often necessitates lifestyle 
modification and use of multiple therapies. There was increased 
use of glucose, lipid and blood pressure lowering treatment 
observed in the study compared with the previous 2009 audit; 
however, results indicated marked improvement in blood pressure 
and lipid levels only. LDL-C has a central role in the pathogenesis of 
CVD in T2DM and this can be minimised through aggressive statin 
therapy. More patients achieved LDL-C targets in the 2013 audit, 
which may be attributed to increased statin utilisation and, in 
addition, some patients were changed to a more potent statin. 
The link between HbA1c and CVD still remains theoretical. In a 
post-hoc analysis of the United Kingdom Prospective Diabetes 
Study (UKPDS) a clear but modest reduction in CVD events was 
demonstrated through tighter glycaemic control.13 In the current 
study, glycaemic control was shown to be the most challenging risk 
factor to correct as it worsened significantly over the study period, 
potentially leading to further risk of CVD events.
Disappointingly, a significant portion of patients still did not 
achieve targets, even those adapting healthier lifestyles or receiving 
more aggressive treatment. Of the total number of patients not at 
target for HbA1c in 2013, most were on insulin. The problem could 
lie with patients not complying with the regimen. One could argue 
that there is a lag period of adoption of guideline recommendations 
by physicians; however, only blood pressure targets changed with 
the release of the newer 2012 guidelines during the study period. 
There may have been reluctance amongst physicians to intensify 
treatment due to assumed poor treatment adherence in patients 
already using multiple drug classes.14,15 Studies have shown that 
patients with diabetes have difficulties with lifestyle modifications 
and are averse to taking medication in general.16,17 Furthermore, as 
Blood pressure management
In the 2013 audit, 99.6% of patient blood pressure values were 
available from files, which is an improvement of 15% compared 
with the measurements in the 2009 audit. More patients reached 
targets (SBP and DBP < 140/80 mmHg) in 2013 (49.6%) than in 2009 
(35.9%) (Figure 1), albeit similar numbers of patients were 
recorded to be receiving treatment (244/261(93.5%) and 236/261 
(90.4%)) during the two time points. Patients used an average of 2.5 
anti-hypertensives over both study periods. A further 63 patients 
(28.6%) reached the combined BP targets in 2013, but 78 (35.5%) 
remained not at goal at both time points. SBP increased, whereas 
DBP decreased compared with 2009 values (Table 1).
In 2013, more females were receiving hypertension treatment than 
males (95.8% vs. 90.7%, p = 0.095), which may have accounted for 
the lower, although not statistically significant SBP (female SBP 
138 mmHg (SD 19.1) vs. male SBP 140 mmHg (SD 25.0), p = 0.556). 
In 2009, females also received more treatment than males (93.0% 
vs. 87.3%, p = 0.118) but had higher systolic blood pressure 
measurements than males (female SBP 136  mmHg (SD 16.2) vs. 
male SBP 131 mmHg (SD 19.4), p = 0.062), both not statistically sig-
nificant.
Over the study period, angiotensin-converting enzyme inhibitors/
angiotensin receptor blockers were the most commonly prescribed 
hypertension treatments and their usage remained constant over 
the study periods (79.7% vs. 79.3%). Also noteworthy is that 
angiotensin receptor blockers’ usage increased from 6.4% to 9.0% 
in 2013.
Lipid management
Lipid monitoring improved, with 97.7% of patients having at least 
one LDL-C measurement available in their records, as opposed to 
the previous 90.8% in the 2009 audit. The mean LDL-C of the study 
population tended to improve over time (2.6  mmol/L (±0.9) vs. 
2.1  mmol/L (±0.9) in 2009 and 2013 respectively). More 
patients without previous cardiovascular disease (CVD) or stroke 
achieved LDL-C targets of 2.5 mmol/L in 2013 (72.7%). Only 47.7% 
achieved target in 2009 (Figure 1). Of these, there were 75 
patients (32.5%) who improved over the time period and 21 
patients (9.1%) who deteriorated, whilst 47 patients (20.3%) 
remained not at goal over both periods.
It was found that 77.8% of patients were using statin lipid-lowering 






























Figure 1: Difference in patients achieving goals between the two time  
periods.
Note: BP = blood pressure, HbA1c = haemoglobin A1c, LDL-C = low-density  
lipoprotein cholesterol, *p < 0.05; **p < 0.001.
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even in a specialised tertiary care setting. In the current study, more 
patients reached blood pressure and LDL-C targets but not HbA1c 
over the four-year period. Improved willingness of physicians to 
monitor risk factors and start additional therapy in the majority of 
T2DM patients was observed (especially lipid-lowering treatment). 
Going forward, more focused advice on lifestyle and therapeutic 
interventions may be necessary to improve the cardiovascular 
outcomes of patients.
Conflict of interest – The authors of this article declare that there is 
no conflict of interest with regard to this work.
References
1.  Mbanya JC, Motala AA, Sobngwi E, et al. Diabetes in sub-Saharan Africa. 
Lancet. 2010;375(9733):2254–66. doi: 10.1016/S0140-6736(10)60550-8. 
PMID: 20609971.
2.  Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for 
vascular disease among adults with previously diagnosed diabe-
tes. JAMA. 2004, 291:335–42. doi:  10.1001/jama.291.3.335. PMID: 
14734596.
3.  UK Prospective Diabetes Study Group. Tight blood pressure 
control and risk of macrovascular and microvascular complications 
in type 2 diabetes. UKPDS 38, BMJ. 1998;317:703–13. doi:  10.1136/
bmj.317.7160.703. PMID: 9732337.
4.  Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention 
of cardiovascular disease with atorvastatin in type 2 diabetes in the 
Collaborative Atorvastatin Diabetes Study (CARDS): multicentre 
randomised placebo-controlled trial. Lancet. 2003;364,685–96. 
doi:  10.1016/S0140-6736(04)16895-5. PMID: 15325833.
5.  Amod A, Motala A, Levitt N, et al. The 2012 SEMDSA guideline for 
the management of type 2 diabetes. JEMDSA. 2012 [cited 2014 Aug 
25];17(1):S1–95. Available from: www.semdsa.org.za/images/2012_
SEMDSA_Guideline_July_FINAL.pdf
6.  Saaddine JB, Cadwell B, Gregg EW, et al. Improvements in diabetes 
processes of care and intermediate outcomes: United States, 1988–2002. 
Ann Intern Med. 2006;144:465–74. doi:  10.7326/0003-4819-144-7-
200604040-00005. PMID: 16585660.
7.  Pinchevsky Y, Butkow N, Raal FJ, et al. The implementation of 
guidelines in a South African population with type 2 diabetes. 
JEMDSA. 2013;18(3):154–8. doi:  10.1080/22201009.2013.10872322.
8.  National guidelines: new revised guidelines for the management 
of type 2 diabetes mellitus at primary healthcare level. Society for 
Endocrinology, Metabolism, and Diabetes of South Africa. 2010 [cited 
2014 Aug 25]. Available from: http://www.semdsa.org.za/files/Diabe-
tes%20Guidelines%202009.pdf
9.  Friedewald WT, Levy RJ, Fredrickson DS. Estimation of low density 
lipoprotein cholesterol in plasma without use of the preparative 
ultracentrifuge. Clin Chem. 1972;18(6):499–502. PMID: 4337382.
10.  Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic 
syndrome: a joint interim statement of the international diabetes 
federation task force on epidemiology and prevention; national heart, 
lung, and blood institute; American heart association; world heart 
federation; international atherosclerosis society; and international 
association for the study of obesity. Circulation. 2009;120:1640–5. 
doi:  10.1161/CIRCULATIONAHA.109.192644. PMID: 19805654.
11.  Seedat YK, Croasdale MA, Milne FJ, et al. Joint national hypertension 
guideline working group. South African hypertension guideline 2006. 
S Afr Med J. 2006;(96):337–62. PMID: 16670808.
12.  Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint 
national committee on prevention, detection, evaluation, and 
treatment of high blood pressure. Hypertension. 2003;42:1206–52. 
doi:  10.1161/01.HYP.0000107251.49515.c2. PMID:14656957.
13.  Irene M, Stratton IM, Adler AI, et al. Association of glycaemia with 
macrovascular and microvascular complications of type 2 diabetes (UK-
PDS 35): prospective observational study. BMJ. 2000;321:405–12. doi: 
10.1136/bmj.321.7258.405. PMID:10938048.
14.  Schmittdiel JA, Uratsu CS, Karter AJ, et al. Why don’t diabetes patients 
achieve recommended risk factor targets? Poor adherence versus 
lack of treatment intensification. J Gen Intern Med. 2008;23:588–94. 
doi: 10.1007/s11606-008-0554-8. PMID: 18317847; PMCID: PMC2324158.
previously seen in the Action to Control Cardiovascular Disease in 
Diabetes (ACCORD), aggressive targeting of HbA1c was harmful to 
certain patients.18 Cost of medication was not a factor in restricting 
physicians from prescribing, as most medications supplied to 
patients in the public sector were government subsidised. The 
findings from the landmark UKPDS indicated that, despite in-
tensification of treatment, disease progression through declining 
pancreatic B-cell function and mass over time cannot be excluded. 
Perhaps the latter can be said about this particular group of 
complicated or possibly treatment-resistant T2DM patients who 
attended the tertiary care setting in this study.19,20
Many prospective studies have identified common co-morbidities 
in T2DM patients. These include obesity, dyslipidaemia and 
hypertension in addition to hyperglycaemia. The Steno-2 study 
revealed the benefits of multiple risk-factor interventions, especially 
in those T2DM patients at high risk.21 In the 2013 audit, more 
patients in comparison with the 2009 audit had weight, smoking 
status, HbA1c, LDL-C and blood pressure levels assessed, which 
may indicate that a more individualised and combined risk approach 
was being implemented.
Patients enrolled in the study did not represent newly diagnosed 
T2DM individuals. Webb et al. screened 599 patients with diabetes 
in the district of Tshwane district and found that HbA1c targets 
were achieved by 27%, with the majority of almost 50% of patients 
in the study having had a self-reported duration of diabetes 
of  <  5  years.22 The average duration of diabetes diagnosis for 
patients in the present study was 16 years (range 2–40).
Not necessarily representing the majority of South African T2DM 
patients, the study focused on those select patients being treated 
at the tertiary level. Unlike patients attending primary care facilities, 
it was assumed that the participants in this retrospective study had 
an advanced form of the disease, necessitating the need for 
specialist care.
Limitations of this study include the large numbers of patients lost 
to follow-up and data being collected at times when files could 
have been in use or not available at the administration office. No 
detailed individual data assessments were carried out on patients 
responding to intensification of treatment. Furthermore, this 
observational study may lend itself to selection or survivor bias in 
that the patients followed up after four years potentially represented 
only a select group of individuals more adherent with their 
treatment regimen. Patients attending this hospital clinic 
undoubtedly have further developed or carry a high risk of 
developing T2DM-related complications. It was assumed that 
practitioners managing these T2DM patients in this study had 
good reason to keep almost 40% of those initially observed 
patients enrolled at this level of care, even after four years.
This study may have undervalued the outcomes achieved at this 
clinic as many of the patients treated have exhausted the therapeutic 
options available to them, reflecting lower numbers of those 
achieving targets. This is not to say that challenges do not exist in 
other, lower levels of healthcare settings. As this was a select group 
of T2DM patients in a specialised setting it may be difficult to 
extrapolate results of these patients to the general diabetes popu-
lation.
Conclusion
Patients with T2DM are burdened with a plethora of diabetes control 
parameters. Studies and guidelines in the management of these 
risk factors exist, yet challenges to reach these targets still remain, 
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